# Crossover Comparison of MultiHance and Dotarem

> **NCT02070380** · PHASE4 · COMPLETED · sponsor: **Bracco Diagnostics, Inc** · enrollment: 179 (actual)

## Conditions studied

- Brain Disease

## Interventions

- **DRUG:** MultiHance 0.1 mmol/kg
- **DRUG:** Dotarem
- **DRUG:** MultiHance 0.05 mmol/kg

## Key facts

- **NCT ID:** NCT02070380
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070380, "Crossover Comparison of MultiHance and Dotarem". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02070380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*